ARIAD Announces Proposed Public Offering of Common Stock

  ARIAD Announces Proposed Public Offering of Common Stock

  Financing to support global commercialization of Iclusig™ (ponatinib) and
    additional clinical development of its investigational targeted cancer

Business Wire

CAMBRIDGE, Mass. -- January 23, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has
commenced an underwritten public offering of shares of its common stock. All
of the shares in the offering are to be sold by ARIAD.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company,
Inc. are acting as joint book-running managers and underwriters for the
proposed offering. ARIAD intends to grant the underwriters a 30-day option to
purchase up to an additional 15 percent of the amount sold to cover
over-allotments, if any. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering.

ARIAD intends to use the net proceeds of this offering for its operations,
including, but not limited to, sales, marketing, manufacturing and
distribution of Iclusig™ (ponatinib); for ongoing global development of its
other product candidates, including clinical trials, product and process
development activities, manufacturing and other activities; expansion of
operations in Europe and other territories to prepare for future commercial
launch of products, if approved; discovery research efforts to add to its
pipeline of product candidates; and for other general corporate purposes,
including, but not limited to, repayment or refinancing of existing
indebtedness or other corporate borrowings, capital expenditures and possible

A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above has been filed with the Securities
and Exchange Commission (the “SEC”) and is effective. A preliminary prospectus
supplement relating to the offering has been filed with the SEC. Copies of the
preliminary prospectus supplement and accompanying prospectus may be obtained
from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number
866-803-9204); the offices of Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number
631-274-2806); or the offices of Jefferies & Company, Inc., Equity Syndicate
Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or
by telephone at 877-547-6340, or by email at

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other


ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the
discovery, development and commercialization of medicines to transform the
lives of cancer patients. For more information about ARIAD, visit the
company’s website at

Forward-looking Statements

Certain of the statements made in this press release are forward looking, such
as those, among others, relating to our expectations regarding the completion
of the proposed public offering, the use of proceeds, and our drug development
and commercialization plans. Actual results or developments may differ
materially from those projected or implied in these forward looking
statements. Factors that may cause such a difference include, without
limitation, risks and uncertainties related to whether or not we will be able
to raise capital through the sale of shares of common stock, the final terms
of the proposed offering, market and other conditions, the satisfaction of
customary closing conditions related to the proposed public offering and the
impact of general economic, industry or political conditions in the United
States or internationally. There can be no assurance that we will be able to
complete the proposed public offering on the anticipated terms, or at all. You
should not place undue reliance on these forward looking statements, which
apply only as of the date of this press release. Additional risks and
uncertainties relating to the proposed offering, ARIAD and our business can be
found under the heading "Risk Factors" in the filings that we periodically
make with the SEC and in the preliminary prospectus supplement related to the
proposed offering filed with the SEC on the date hereof. In addition, the
forward-looking statements included in this press release represent our views
as of the date of this press release. We anticipate that subsequent events and
developments will cause our views to change. However, while we may elect to
update these forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so. These forward-looking
statements should not be relied upon as representing our views as of any date
subsequent to the date of this press release.


ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
For Media
Liza Heapes, 617-621-2315
Press spacebar to pause and continue. Press esc to stop.